The goal of this project is to develop a commercial product with the
capacity to enhance erythrocyte CR1 receptors. Additional information is
considered proprietary.
IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
-
Activity
R43
-
Administering IC
AI
-
Application Type
1
-
Direct Cost Amount
-
Indirect Cost Amount
-
Total Cost
-
Sub Project Total Cost
-
ARRA Funded
-
CFDA Code
855
-
Ed Inst. Type
-
Funding ICs
-
Funding Mechanism
-
Study Section
SSS
-
Study Section Name